交银国际:升康方生物(09926)目标价至92港元 依沃西将迎多项关键性进展

智通财经
01 Apr

智通财经APP获悉,交银国际发布研报称,康方生物(09926)去年的产品销售强劲增长。该行预计集团的医保覆盖将带动集团今年进一步销售放量、并实现盈亏平衡。该行表示,随着依沃西的海外注册研究进入冲刺阶段,更多新型抗体、ADC和自免领域候选药物进入临床开发,公司管线价值持续增厚,上调目标价至92港元,评级为“买入”。

康方生物去年及去年下半年的业绩胜预期,列账纯利及non-IFRS(非国际财务报告准则)纯利或有可能在今年末首次同比录得正数。另外,该行目前预期公司可在今年末录得列账纯利2300万港元,以及non-IFRS纯利1.03亿港元;同时亦上调了2026年经调整盈利预测3%至12亿港元。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10